Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAL-PEP
2011-003799-35Phase 4Active
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Oct 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of raltegravir, lopinavir, ritonavir and emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: Treatment completion within 28 days. Started Oct 2011; status: active.
02
Drugs
raltegravirlopinavirritonaviremtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2011-003799-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003799-35.